Status:
COMPLETED
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Bone Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Documented bone metastases from breast cancer, prostate cancer or multiple myeloma
- Prior treatment with zoledronic acid for 1-2 yrs
- Life expectancy of at least 6 months
- Exclusion criteria:
- Prior treatment with bisphosphonates other than zoledronic acid
- Abnormal kidney function
- Current or previous dental problems or planned dental surgery
- Pregnant or likely to become pregnant during the study
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00434447
Start Date
December 1 2006
Last Update
February 27 2017
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Canberra, Australian Capital Territory, Australia
2
Novartis Investigative Site
Concord, New South Wales, Australia
3
Novartis Investigative Site
Liverpool, New South Wales, Australia
4
Novartis Investigative Site
Wagga Wagga, New South Wales, Australia